“Dangling” Accelerated Approvals in Oncology | NEJM
Perspective from The New England Journal of Medicine — “Dangling” Accelerated Approvals in Oncology
Related Articles
Professional Education and Resources
Oncology Center of Excellence professional education projects and resources – 2023 OCE Annual Report
FDA grants accelerated approval to tovorafenib for patients with relap
On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months
Conversations on Cancer: Strength in Numbers, Increasing Cancer Awareness and Decreasing Disparities
April is National Minority Health Month created to reduce health disparities and raise awareness about improving the health of racial and ethnic minority com…
FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis compan
FDA grants accelerated approval to tovorafenib for patients with relap
On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months
FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis compan
FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years
On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis compan
Conversations on Cancer: Strength in Numbers
FDA Oncology Center of Excellence Presents: Conversations on Cancer: Strength in Numbers, Increasing Cancer Awareness while Decreasing Disparities
FDA approves nogapendekin alfa inbakicept-pmln for bladder cancer
On April 22, 2024, the FDA approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) for non-muscle invasive bladder cancer.